August 20, 2004Anesthesiology
A Large Trial Is Vital to Prove Perioperative β-blockade Effectiveness and Safety before Widespread Use
Key result
Perioperative β-blockade for noncardiac surgery lacks definitive evidence, as current data from 866 randomized patients are insufficient to justify widespread recommendations.
Why the study?
Does perioperative beta-blockade reduce cardiac death and myocardial infarction in high-risk patients undergoing noncardiac surgery?
Population
High-risk patients undergoing noncardiac surgery
Design
Editorial
Authors
Discussion
Loading...
Member takes
Implication
Widespread use of perioperative beta-blockers in noncardiac surgery is not justified by current small, flawed trials and requires confirmation from large-scale RCTs.
Structured PICO
Does perioperative beta-blockade reduce cardiac death and myocardial infarction in high-risk patients undergoing noncardiac surgery?
P
Population
High-risk patients undergoing noncardiac surgery
I
Intervention
Perioperative beta-blockade
Widespread use of perioperative beta-blockers in noncardiac surgery is not justified by current small, flawed trials and requires confirmation from large-scale RCTs.
Limitations
- Current evidence is based on small trials with methodological flaws such as lack of blinding, early stopping, and selective event counting
- Safety data are lacking regarding age, acute beta-blockade, blood loss, and other pharmacologic interventions
- No consensus on logistics of perioperative blockade (dose, duration, route)
Cite This Study
Leslie et al. (2004) conducted an editorial in High-risk patients undergoing noncardiac surgery. Perioperative β-blockade was evaluated. Perioperative β-blockade for noncardiac surgery lacks definitive evidence, as current data from 866 randomized patients are insufficient to justify widespread recommendations.